When a Multinational Rethinks Its Core: The Day Zimmer Biomet’s Strategy Met an Urgent Question

I’m a product strategy coordinator at a large medical device manufacturer—think big corporate, 20,000+ employees, and a brand that’s synonymous with orthopedic and dental implants. I’ve handled over 200 product launch and portfolio rationalization projects in the last six years. In my role, urgency isn’t usually a factor—we plan 18 months out. But every so often, a question lands on my desk that throws all the projections out the window.

The Question That Changed Our Q2

It was March 2024. Our VP of Commercial Strategy walked into a weekly review with a single slide: “Zimmer Biomet corporate address is fine, industry is fine—what isn’t fine is our adjacency portfolio. We need to decide: Do we double down on robotics (ROSA) or expand into emerging therapy areas? And we need to brief the board in 36 hours.”

Suddenly, my carefully planned Gantt chart for the quarter was useless. We had less than two days to assemble a recommendation on our future product direction—covering everything from our core orthopedic implant lines to adjacent devices like nebulizer machines and shockwave therapy devices, which some of our European distributors were already piloting.

At first, I thought the request was borderline absurd. Nebulizer machines? Shockwave therapy? How does PCR work?—that was the third search term in our briefing pack. Our strength is implants and surgical robotics, not respiratory care or physical therapy equipment. But the data from our distribution channels was clear: hospitals were asking for bundled solutions. They wanted a single procurement partner who could supply not just the Persona knee or the Taperloc hip, but also the post-op recovery devices and the diagnostic tools.

The Messy Middle: What We Actually Did

I won’t pretend we had a smooth process. I’m not a respiratory therapist, so I can’t speak to the clinical nuances of how does PCR work in a point-of-care setting versus a centralized lab. What I can tell you from a strategy perspective is that we had three options on the table by hour 12:

• Option A: Stay pure-play orthopedics & dental. Ignore the nebulizer and shockwave data.
• Option B: License or acquire a small med-tech firm that already had FDA clearance for shockwave therapy devices and nebulizer machines.
• Option C: Partner with a diagnostic company to co-market PCR-based infection detection kits for pre-surgical screening (a natural fit for our dental implant business, where peri-implantitis is a major concern).

I went back and forth between Option B and Option C for nearly six hours. Option B offered immediate adjacency revenue (our European distributor was forecasting $4M in shockwave device sales for 2025). Option C offered strategic depth—how does PCR work in detecting bacteria before implant surgery? It’s a genuinely compelling value proposition: reduce infection rates, improve outcomes. But partnering meant slower execution.

Honestly, I’m not sure why the team was so split. My best guess is that we each had a different definition of “urgent.” Procurement wanted revenue; Regulatory wanted time; I wanted certainty.

The Decision (and the Immediate Second-Guessing)

We recommended Option C to the board: a strategic partnership with a diagnostic firm. The logic was that it leveraged our existing surgical workflow expertise (think ROSA, surgical techniques) without diluting our brand into commodity devices. We’d support the shockwave and nebulizer demand through a separate distribution agreement, but not manufacturing.

The VP nodded. Approved. Hit “send” on the board pack.

And I immediately thought: Did we just lose the $4M shockwave opportunity? Could we have done both?

The three weeks until the partnership term sheet was signed were stressful. Every time I saw a competitor’s shockwave device ad at a trade show, I winced. This gets into the territory of “coulda, woulda, shoulda,” which isn’t my expertise. I’d recommend consulting a corporate development specialist before making a similar call. But from a strategy perspective, the partnership route gave us something more valuable than short-term adjacency revenue: a credible long-term narrative for hospitals.

The Lesson: Time Certainty Has a Price (and a Premium)

Here’s what I took away from that two-day fire drill. In an emergency situation—whether it’s a board briefing or a last-minute procurement decision—the value of delivery certainty is real. The “maybe we can” option is the enemy of the “we will” commitment.

This was true 20 years ago when digital options were limited. Today, with rapid prototyping, strategic partnerships, and supply chain flexibility, you can move fast—but moving fast isn’t the same as moving with certainty.

In March 2024, we paid for certainty: we chose a slower, safer partnership over a faster acquisition. The alternative was a regulatory delay that would have cost us Q3 2025 product launches.

Does that mean you should always pay the premium for guaranteed timing? No. But when the question is existential—“What is our future strategy?”—uncertainty is more expensive than any rush fee.

Practical Takeaways for Your Next Urgent Decision

If you’re ever in a situation where you need to make a rapid portfolio or procurement decision (and you will be), here are three rules I now follow:

1. Know your core expertise and stay in your lane. We’re a surgical implant company. Nebulizer machines and shockwave therapy devices are valid products, but they’re not our products. Partner, don’t pivot.
2. Use precise data, not vague trends. “Our distributors sold $4M in shockwave devices last year” is actionable. “In recent years…” is not. Anchor your decision in numbers with a timestamp (like the Q3 2024 channel data we used).
3. Build buffer into your process. We paid $0 extra in rush fees for this project—but we did burn three weekends. The real cost was team exhaustion. Next time, I’ll insist on a 48-hour buffer before presenting to the board, even if it means pushing the meeting.

One last thing: I’ve never fully understood why some organizations treat “urgent” as a license to abandon rigor. The best emergency decisions I’ve seen are the ones that slow down just enough to get the facts right. Speed is not a substitute for accuracy. (Note to self: remember this when the next VP walks in unannounced.)